1. Home
  2. HDL vs RLMD Comparison

HDL vs RLMD Comparison

Compare HDL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$13.40

Market Cap

829.7M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.33

Market Cap

752.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
RLMD
Founded
2016
2004
Country
Singapore
United States
Employees
14003
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
829.7M
752.1M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
HDL
RLMD
Price
$13.40
$6.33
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
2.8K
925.0K
Earning Date
05-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
$14.73
N/A
Revenue Next Year
$12.94
N/A
P/E Ratio
$55.56
N/A
Revenue Growth
N/A
154.83
52 Week Low
$13.11
$0.52
52 Week High
$21.21
$8.00

Technical Indicators

Market Signals
Indicator
HDL
RLMD
Relative Strength Index (RSI) 42.55 37.07
Support Level $13.21 $6.17
Resistance Level $15.21 $7.46
Average True Range (ATR) 0.24 0.41
MACD 0.02 -0.11
Stochastic Oscillator 16.91 14.49

Price Performance

Historical Comparison
HDL
RLMD

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: